Imagine being told that a potentially life-saving vaccine, one that could protect your newborn from a debilitating disease, might be deliberately withheld. That's the ethical minefield a now-cancelled US-funded study in Guinea-Bissau walked straight into, sparking international outrage and accusations of exploitation. A controversial research project, designed to study hepatitis B vaccines in newborns, has been halted following a wave of criticism. Yap Boum, a high-ranking official at the Africa Centres for Disease Control and Prevention (CDC), confirmed the cancellation at a press conference.
This $1.6 million study, backed by Robert F Kennedy Jr. (a well known vaccine skeptic) through his role at the US Department of Health and Human Services (HHS), ignited fury due to the perceived ethical implications of denying proven hepatitis B vaccines to infants in a nation where the disease is alarmingly prevalent. Hepatitis B can lead to serious long-term health problems, including liver cirrhosis and cancer, especially if contracted at a young age. In Guinea-Bissau, approximately 18% of adults and 11% of children under one year old are affected by the disease.
"It’s of importance for Africa CDC to have evidence that can be translated in policy, but this has to be done within the norm," Boum stated. "The way the study was designed was a big challenge." The primary concern revolved around the ethics of the trial's design, which raised serious questions about fairness and potential harm to the participants.
But here's where it gets controversial... While Africa CDC officials have celebrated the cancellation, stating that the trial will only proceed if redesigned to address ethical concerns, officials within Guinea-Bissau have indicated that the trial will still happen. These conflicting statements highlight ongoing tensions and negotiations between Guinea-Bissau officials and the US regarding the ethical execution of such research. The Africa CDC has assembled a team to ensure Guinea-Bissau receives support in adhering to ethical regulations if the study is to continue. The recent coup in Guinea-Bissau, which resulted in a complete change of top officials (including within the health ministry), adds another layer of complexity to the situation.
Dr. Paul Offit, an infectious diseases physician at Children’s Hospital of Philadelphia and a former member of the FDA's vaccine advisory committee, expressed immense relief at the news. "This administration did not see people in Africa as valuable," Offit stated, drawing a stark conclusion about the study's underlying implications. "You can’t treat children like this, you can’t treat people like this. We were able to stand up for them. We were able to convince people about the fact that this was unethical.” The HHS has not yet commented on the reasons for the trial's cancellation.
This event could mark a turning point for Guinea-Bissau and other nations grappling with potentially unethical research practices. Boghuma Titanji, an assistant professor of medicine at Emory University specializing in vaccine misinformation in Africa, believes that this cancellation demonstrates that institutions are becoming more assertive in challenging exploitative research in Africa. Titanji views the trial's original design as "damaging," with potentially far-reaching negative consequences.
The researchers behind the study argued that it would provide the vaccine to 7,000 newborns who would otherwise not receive it. And this is the part most people miss... While that sounds benevolent, the trial design meant that another 7,000 children would be denied the vaccine due to random assignment, knowingly depriving them of a potentially life-saving intervention. Offit argued that the $1.6 million should instead be directly used to vaccinate as many children as possible at birth. Guinea-Bissau currently recommends hepatitis B vaccination at six weeks of age due to access challenges, but plans to shift to vaccination at birth by 2027 as vaccine availability improves.
Offit even drew a sobering parallel to the infamous Tuskegee experiment, where African American men with syphilis were deliberately denied effective treatment. The Danish researchers leading the trial have faced previous criticism for allegedly withholding publication of a DTP vaccine study that contradicted their beliefs about vaccine safety.
While the full study protocols remain unpublished, leaked versions and researcher commentary have surfaced. Titanji expressed skepticism about the researchers' justifications, stating that they raised even more concerns. The researchers argued that live vaccines might have nonspecific health benefits, and that introducing the hepatitis B vaccine could interfere with these effects. However, the evidence supporting these nonspecific effects relies heavily on the researchers' own prior research, which has faced scrutiny. A new, yet-to-be peer-reviewed study by other Danish researchers found no statistically significant evidence of such effects.
The Danish researchers have further argued that trials should be conducted in Africa to specifically study the vaccine effects on African children. Titanji agrees that more randomized controlled trials are needed in Africa, but insists they should be led by African scientists and driven by questions relevant to African communities. She describes projects like the Danish study as potentially exploitative, taking advantage of vaccine scarcity in contexts where they are desperately needed.
What's truly disturbing is that the study, as originally designed, would be "exploiting a window where the government is not able to provide that intervention to its citizens," as Titanji puts it. It's not solving the problem; it's arguably contributing to it.
The trial was scheduled to begin on January 5th. The lead researchers, Peter Aaby and Christine Stabell Benn, have disputed previous reports citing ethical concerns, claiming they were based on insufficient evidence. These researchers have close ties to Trump administration health officials, including Tracy Beth Høeg, now an FDA official who has worked on post-COVID vaccination mortality and advocated for aligning US vaccine recommendations with Denmark's more limited schedule.
Robert F. Kennedy Jr. has praised Aaby's research, citing it as evidence that the DTP vaccine is deadly – a claim he used to justify ending funding to Gavi, the Vaccine Alliance. However, he conveniently omitted that Aaby's team found drastically different results in a subsequent study just the year before.
This situation raises some fundamental questions: Should wealthier nations be allowed to conduct studies in developing countries that would be deemed unethical in their own? What responsibility do researchers have to ensure equitable access to healthcare for all participants, even during a trial? And perhaps most importantly, how can we ensure that research conducted in vulnerable populations is truly beneficial and not exploitative? What are your thoughts? Do you believe this study was inherently unethical, or were the researchers' intentions genuinely aimed at improving healthcare outcomes? Let us know in the comments below!
